In Vitro to In Vivo Extrapolation from Three-Dimensional hiPSC-Derived Cardiac Microtissues and Physiologically Based Pharmacokinetic Modeling to Inform Next-Generation Arrhythmia Risk Assessment

Scientists expanded the capacity of their previously established three-dimensional human cardiac microtissue model to perform quantitative risk assessment by combining it with a physiologically based pharmacokinetic model, allowing a direct comparison of potentially harmful concentrations predicted in vitro to in vivo therapeutic levels.